Endogenous Production of IL1B by Breast Cancer Cells Drives Metastasis and Colonization of the Bone Microenvironment.


Journal

Clinical cancer research : an official journal of the American Association for Cancer Research
ISSN: 1557-3265
Titre abrégé: Clin Cancer Res
Pays: United States
ID NLM: 9502500

Informations de publication

Date de publication:
01 05 2019
Historique:
received: 11 07 2018
revised: 20 11 2018
accepted: 17 01 2019
pubmed: 24 1 2019
medline: 20 6 2020
entrez: 24 1 2019
Statut: ppublish

Résumé

Breast cancer bone metastases are incurable, highlighting the need for new therapeutic targets. After colonizing bone, breast cancer cells remain dormant, until signals from the microenvironment stimulate outgrowth into overt metastases. Here we show that endogenous production of IL1B by tumor cells drives metastasis and growth in bone. Tumor/stromal IL1B and IL1 receptor 1 (IL1R1) expression was assessed in patient samples and effects of the IL1R antagonist, Anakinra, or the IL1B antibody canakinumab on tumor growth and spontaneous metastasis were measured in a humanized mouse model of breast cancer bone metastasis. Effects of tumor cell-derived IL1B on bone colonization and parameters associated with metastasis were measured in MDA-MB-231, MCF7, and T47D cells transfected with In tissue samples from >1,300 patients with stage II/III breast cancer, IL1B in tumor cells correlated with relapse in bone (HR = 1.85; 95% CI, 1.05-3.26; Pharmacologic inhibition of IL1B has potential as a novel treatment for breast cancer metastasis.

Identifiants

pubmed: 30670488
pii: 1078-0432.CCR-18-2202
doi: 10.1158/1078-0432.CCR-18-2202
doi:

Substances chimiques

IL1B protein, human 0
Interleukin-1beta 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2769-2782

Subventions

Organisme : Medical Research Council
ID : MR/P000096/1
Pays : United Kingdom

Informations de copyright

©2019 American Association for Cancer Research.

Auteurs

Claudia Tulotta (C)

Department of Oncology and Metabolism, University of Sheffield, Sheffield, United Kingdom.

Diane V Lefley (DV)

Department of Oncology and Metabolism, University of Sheffield, Sheffield, United Kingdom.

Katy Freeman (K)

Department of Oncology and Metabolism, University of Sheffield, Sheffield, United Kingdom.

Walter M Gregory (WM)

Leeds Institute of Clinical Trials Research, Leeds, United Kingdom.

Andrew M Hanby (AM)

Institute of Molecular Medicine, St James's University Hospital, Leeds, United Kingdom.

Paul R Heath (PR)

Sheffield Institute for Translational Neuroscience, University of Sheffield, Sheffield, United Kingdom.

Faith Nutter (F)

Department of Oncology and Metabolism, University of Sheffield, Sheffield, United Kingdom.

J Mark Wilkinson (JM)

Department of Oncology and Metabolism, University of Sheffield, Sheffield, United Kingdom.

Amy R Spicer-Hadlington (AR)

Department of Oncology and Metabolism, University of Sheffield, Sheffield, United Kingdom.

Xinming Liu (X)

Department of Oncology and Metabolism, University of Sheffield, Sheffield, United Kingdom.

Steven M J Bradbury (SMJ)

Department of Oncology and Metabolism, University of Sheffield, Sheffield, United Kingdom.

Lisa Hambley (L)

Department of Oncology and Metabolism, University of Sheffield, Sheffield, United Kingdom.

Victoria Cookson (V)

Department of Oncology and Metabolism, University of Sheffield, Sheffield, United Kingdom.

Gloria Allocca (G)

Department of Oncology and Metabolism, University of Sheffield, Sheffield, United Kingdom.

Marianna Kruithof de Julio (M)

Department of Biomedical Research, University of Bern, Bern, Switzerland.

Robert E Coleman (RE)

Department of Oncology and Metabolism, University of Sheffield, Sheffield, United Kingdom.

Janet E Brown (JE)

Department of Oncology and Metabolism, University of Sheffield, Sheffield, United Kingdom.

Ingunn Holen (I)

Department of Oncology and Metabolism, University of Sheffield, Sheffield, United Kingdom.

Penelope D Ottewell (PD)

Department of Oncology and Metabolism, University of Sheffield, Sheffield, United Kingdom. p.d.ottewell@sheffield.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH